The Agency and the Federal Office for Customs and Border Security (FOCBS), after weighing up the interests, are entitled on a case-by-case basis to disclose confidential data collected in accordance with this Act to the holder of an operating licence or of a marketing authorisation for medicinal products or to any person who places a medical device on the market, including sensitive personal data in accordance with Article 5 letter c number 5 of the Data Protection Act of 25 September 20201, provided this measure is regarded as necessary in order to uncover or combat suspected illegal trading in therapeutic products.2
Personal data relating to patients may not be disclosed.